DE602005018800D1 - Verfahren zur herstellung von polypeptidmischungen unter anwendung von aufgereinigter bromwasserstoffsäure - Google Patents

Verfahren zur herstellung von polypeptidmischungen unter anwendung von aufgereinigter bromwasserstoffsäure

Info

Publication number
DE602005018800D1
DE602005018800D1 DE602005018800T DE602005018800T DE602005018800D1 DE 602005018800 D1 DE602005018800 D1 DE 602005018800D1 DE 602005018800 T DE602005018800 T DE 602005018800T DE 602005018800 T DE602005018800 T DE 602005018800T DE 602005018800 D1 DE602005018800 D1 DE 602005018800D1
Authority
DE
Germany
Prior art keywords
purificed
production
hydrogen acid
polypeptide mixtures
bromine hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005018800T
Other languages
English (en)
Inventor
Ben-Zion Dolitzky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36037047&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602005018800(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of DE602005018800D1 publication Critical patent/DE602005018800D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE602005018800T 2004-09-09 2005-09-09 Verfahren zur herstellung von polypeptidmischungen unter anwendung von aufgereinigter bromwasserstoffsäure Active DE602005018800D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60884304P 2004-09-09 2004-09-09
PCT/US2005/032395 WO2006029393A2 (en) 2004-09-09 2005-09-09 Process for preparation of mixtures of polypeptides using purified hydrobromic acid

Publications (1)

Publication Number Publication Date
DE602005018800D1 true DE602005018800D1 (de) 2010-02-25

Family

ID=36037047

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005018800T Active DE602005018800D1 (de) 2004-09-09 2005-09-09 Verfahren zur herstellung von polypeptidmischungen unter anwendung von aufgereinigter bromwasserstoffsäure

Country Status (28)

Country Link
US (2) US7495072B2 (de)
EP (3) EP2361924B1 (de)
JP (1) JP5149008B2 (de)
KR (1) KR101317131B1 (de)
CN (1) CN101166754B (de)
AT (2) ATE454396T1 (de)
AU (1) AU2005282249B2 (de)
BR (1) BRPI0515033B1 (de)
CA (1) CA2579656C (de)
CY (1) CY1110280T1 (de)
DE (1) DE602005018800D1 (de)
DK (3) DK2177528T3 (de)
ES (3) ES2338138T3 (de)
HK (3) HK1100780A1 (de)
HR (3) HRP20100164T1 (de)
IL (2) IL181596A (de)
IS (1) IS8622A (de)
MX (1) MX2007002760A (de)
NO (1) NO20071632L (de)
NZ (1) NZ554018A (de)
PL (3) PL1799703T3 (de)
PT (3) PT2177528E (de)
RS (3) RS53248B (de)
RU (1) RU2388764C2 (de)
SI (3) SI2177528T1 (de)
UA (1) UA91029C2 (de)
WO (1) WO2006029393A2 (de)
ZA (1) ZA200702591B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
WO2000005250A1 (en) 1998-07-23 2000-02-03 Yeda Research And Development Co., Ltd Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
WO2002076503A1 (en) * 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
SI1459065T1 (sl) * 2001-12-04 2010-11-30 Teva Pharma Postopki za merjenje potentnosti glatiramer acetata
WO2005084377A2 (en) * 2004-03-03 2005-09-15 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and riluzole
EP1797109B1 (de) * 2004-09-09 2016-02-24 Yeda Research And Development Co., Ltd. Mischungen von polypeptiden, zusammensetzungen, die diese enthalten, und verfahren zu deren herstellung, und deren anwendungen
DE602005018800D1 (de) 2004-09-09 2010-02-25 Teva Pharma Verfahren zur herstellung von polypeptidmischungen unter anwendung von aufgereinigter bromwasserstoffsäure
JP5297653B2 (ja) * 2004-10-29 2013-09-25 サンド・アクチエンゲゼルシヤフト グラチラマーの製造法
US8324641B2 (en) * 2007-06-29 2012-12-04 Ledengin, Inc. Matrix material including an embedded dispersion of beads for a light-emitting device
UA93669C2 (ru) * 2005-02-02 2011-03-10 Тева Фармасьютикл Индастриз, Лтд. Способ приготовления полипептидной смеси c использованием гидрогенолиза
RS52867B (en) * 2005-02-17 2013-12-31 Teva Pharmaceutical Industries Ltd. GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS
US20060240463A1 (en) * 2005-04-25 2006-10-26 Rappaport Family Institute For Research In The Medical Sciences Markers associated with the therapeutic efficacy of glatiramer acetate
US20090035816A1 (en) * 2007-08-02 2009-02-05 Scinopharm Taiwan Ltd. Process for the preparation of a polypeptide
JP2011504925A (ja) * 2007-11-28 2011-02-17 テバ ファーマシューティカル インダストリーズ リミティド 臨床的に確実な多発性硬化症の発症を遅延させる方法
EP2277050B2 (de) 2008-04-16 2022-09-28 Momenta Pharmaceuticals, Inc. Analyse von aminosäurecopolymerzusammensetzungen
JP2011530523A (ja) * 2008-08-07 2011-12-22 サイノファーム タイワン リミテッド 酢酸グラチラマーの合成
PL2307448T3 (pl) * 2008-08-07 2015-10-30 Sigma Aldrich Co Llc Wytwarzanie polilizyny i poliornityny o małym ciężarze cząsteczkowym z wysoką wydajnością
WO2010115175A1 (en) 2009-04-03 2010-10-07 Momenta Pharmaceticals, Inc. Control of copolymer compositions
EP2405749B1 (de) 2009-08-20 2013-05-08 Yeda Research and Development Co., Ltd. Niedrigfrequente glatiramerazetattherapie
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
MX2012012489A (es) * 2010-04-27 2012-12-17 Reddys Lab Ltd Dr Preparacion de polipeptidos y sales de los mismos.
NZ609938A (en) 2010-10-11 2015-11-27 Teva Pharma Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
US9029507B2 (en) * 2011-02-14 2015-05-12 Usv Limited Copolymer-1, process for preparation and analytical methods thereof
JP5701103B2 (ja) * 2011-03-02 2015-04-15 昭和シェル石油株式会社 潤滑油のための消泡剤組成物及びそれを用いた消泡方法
ES2601892T3 (es) 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
WO2013009864A1 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Structure assessment of heterogeneous polypeptide mixtures
WO2013009885A2 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Evaluation of copolymer diethylamide
US8575198B1 (en) 2011-09-07 2013-11-05 Momenta Pharmaceuticals, Inc. In-process control for the manufacture of glatiramer acetate
TW201326399A (zh) 2011-10-10 2013-07-01 Teva Pharma 用於預測對格拉替雷（ｇｌａｔｉｒａｍｅｒ）醋酸鹽之臨床反應之單核苷酸多型性之判定
CN102717992A (zh) * 2012-05-30 2012-10-10 苏州市旭洋工业搪瓷厂 一种搪玻璃溴素贮罐
CN102718963B (zh) * 2012-06-19 2014-10-15 深圳翰宇药业股份有限公司 聚合物多肽的制备方法
US9617596B2 (en) 2012-10-10 2017-04-11 Teva Pharmaceutical Industries, Ltd. Biomarkers predictive for clinical response for glatiramer acetate
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
US20170165236A1 (en) 2013-11-01 2017-06-15 Celgene International Ii Sàrl Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith
CN104844697B (zh) * 2014-09-26 2018-10-23 深圳翰宇药业股份有限公司 醋酸格拉替雷的制备方法
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
EP3600553A4 (de) 2017-03-26 2020-09-02 Mapi Pharma Ltd. Glatiramerdepotsysteme zur behandlung progressiver formen von multipler sklerose
US20190202984A1 (en) * 2018-01-03 2019-07-04 Kinbio Ltd. Process of preparing glatiramer acetate

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3846550A (en) 1971-01-21 1974-11-05 H Akrongold Cosmetic skin powder containing urea
IL36670A (en) * 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
JPS54119499A (en) * 1978-03-09 1979-09-17 Shionogi & Co Ltd Triazolobenzodiazepin derivative
JPS6053535A (ja) 1983-09-02 1985-03-27 Nitto Boseki Co Ltd 規則性ポリアミノ酸樹脂の製造方法
SU1182051A1 (ru) 1984-04-28 1985-09-30 Таджикский государственный университет им.В.И.Ленина Политрипептиды,обладающие энантовой селективностью в реакци х гидролиза @ -нитрофениловых эфиров карбобензокси - @ - и @ -аланина
AR247097A1 (es) 1985-06-18 1994-11-30 Univ Emory Procedimiento para preparar composiciones farmaceuticas que incluyen copolimeros biologicamente activos como agente activo.
DD257174A3 (de) 1985-12-20 1988-06-08 Ve Forschungszentrum Biotechno Verfahren zur herstellung der peptide z-ala-ala-lon-p-nitranilid oder z-asp-phe-ome mit metalloprotease
SU1469826A1 (ru) 1986-05-30 1995-11-20 Институт Высокомолекулярных Соединений Ан Ссср Сополимер l-лизина с l-глутаминовой кислотой, содержащий дофаминовые боковые группы, обладающий пролонгированной гипотензивной активностью и компенсаторным эффектом при геморрагическом шоке, и способ его получения
SU1690368A1 (ru) 1989-07-20 1995-08-20 Институт Высокомолекулярных Соединений Ан Ссср Статистические сополимеры в качестве низкотоксичных веществ, обладающих пролонгированным гипотензивным действием, и способ их получения
DE3930733A1 (de) 1989-09-14 1991-03-28 Roehm Gmbh Verfahren zur herstellung eines komplexierten arzneimittels
USH1312H (en) * 1992-05-28 1994-05-03 Cytogen Corporation Method for the preparation of gyk-dtpa
US5800808A (en) 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US5858964A (en) 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
FR2750423B1 (fr) 1996-06-28 1998-08-14 Rhone Poulenc Chimie Procede d'hydrogenation asymetrique d'un compose cetonique
US6214791B1 (en) 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
BR9815377A (pt) 1997-09-30 2001-01-16 Daiichi Pharmaceutical Co Ltda Derivados de sulfonil
US5872122A (en) * 1997-10-16 1999-02-16 Monsanto Company Pyrimidinylamidino β-amino acid derivatives useful as inhibitors of platelet aggregation
US5965047A (en) 1997-10-24 1999-10-12 Steag Ast Rapid thermal processing (RTP) system with rotating substrate
GB9724627D0 (en) 1997-11-20 1998-01-21 Genencor Int Bv Gram positive microorganism formate pathway
WO2000005250A1 (en) 1998-07-23 2000-02-03 Yeda Research And Development Co., Ltd Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6514938B1 (en) 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
WO2000027417A1 (en) 1998-11-12 2000-05-18 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd
US6114649A (en) 1999-07-13 2000-09-05 Duran Technologies Inc. Anode electrode for plasmatron structure
EP1250450A2 (de) 1999-09-03 2002-10-23 University of Iowa Research Foundation Inc. "quorum sensing" signale in bakterien
DE19944003C1 (de) 1999-09-14 2001-03-22 Baumeister & Ostler Gmbh Co Faltbare Trenneinrichtung
AU780188B2 (en) * 2000-01-20 2005-03-03 Yeda Research And Development Co. Ltd. The use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy
ZA200206457B (en) 2000-02-18 2003-08-13 Yeda Res & Dev Oral, nasal and pulmonary dosage formulations of copolymer 1.
AU2001238469C1 (en) 2000-02-18 2006-08-24 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2001093893A2 (en) 2000-06-07 2001-12-13 Yeda Research And Development Co. Ltd. The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
JP3698984B2 (ja) 2000-11-10 2005-09-21 ヤマウチ株式会社 シュープレス用ベルト
JP2004517074A (ja) * 2000-11-20 2004-06-10 ファルマシア・コーポレーション 凝血カスケードを選択的に阻害するのに有用な置換された多環アリールおよびヘテロアリールピリジン類
JP3661935B2 (ja) 2001-06-20 2005-06-22 ソニー株式会社 情報処理装置および方法、記録媒体、並びにプログラム
SI1459065T1 (sl) * 2001-12-04 2010-11-30 Teva Pharma Postopki za merjenje potentnosti glatiramer acetata
AU2003301457A1 (en) 2002-05-09 2004-05-04 Keith Baumann Bioweapon-detecting fibrous-network products and methods for making same
EP1565486A2 (de) * 2002-11-13 2005-08-24 Apotex Pharmachem Inc. Verfahren zur herstellung von glatirameracetat durch polymerisierung von n-carbonsäureanhydriden vonl-alanin, l-tyrosin, benzyl-l-glutamat und benzyloxycarbonyl-l-lysin
CA2411786C (en) 2002-11-13 2009-01-27 Brantford Chemicals Inc. A process for the preparation of polypeptides from n-carboxyanhydrides of amino acids
DE10353960B4 (de) 2003-10-16 2006-03-23 Vertilas Gmbh Oberflächenemittierender Halbleiterlaser mit strukturiertem Wellenleiter
EP1797109B1 (de) * 2004-09-09 2016-02-24 Yeda Research And Development Co., Ltd. Mischungen von polypeptiden, zusammensetzungen, die diese enthalten, und verfahren zu deren herstellung, und deren anwendungen
DE602005018800D1 (de) 2004-09-09 2010-02-25 Teva Pharma Verfahren zur herstellung von polypeptidmischungen unter anwendung von aufgereinigter bromwasserstoffsäure
UA93669C2 (ru) 2005-02-02 2011-03-10 Тева Фармасьютикл Индастриз, Лтд. Способ приготовления полипептидной смеси c использованием гидрогенолиза
US20060240463A1 (en) * 2005-04-25 2006-10-26 Rappaport Family Institute For Research In The Medical Sciences Markers associated with the therapeutic efficacy of glatiramer acetate
WO2007072865A1 (ja) 2005-12-22 2007-06-28 Pioneer Corporation 施設情報配信装置、通信端末、施設情報配信方法、情報出力方法、プログラム、および記録媒体

Also Published As

Publication number Publication date
IL181596A0 (en) 2007-07-04
HRP20120209T1 (hr) 2012-06-30
EP2177528B1 (de) 2011-12-07
IL241702A0 (en) 2015-11-30
WO2006029393A3 (en) 2007-12-13
ES2382298T3 (es) 2012-06-07
PT2177528E (pt) 2012-03-19
EP2177528A1 (de) 2010-04-21
AU2005282249B2 (en) 2012-08-02
HRP20100164T1 (hr) 2010-07-31
CN101166754A (zh) 2008-04-23
US7495072B2 (en) 2009-02-24
US20070021324A1 (en) 2007-01-25
IS8622A (is) 2007-03-16
DK2361924T3 (en) 2014-03-10
HK1100780A1 (en) 2007-09-28
EP1799703A4 (de) 2008-09-03
RU2388764C2 (ru) 2010-05-10
ZA200702591B (en) 2009-03-25
PL1799703T3 (pl) 2010-06-30
PL2177528T3 (pl) 2012-09-28
PT1799703E (pt) 2010-03-04
RS52265B (en) 2012-10-31
HK1140775A1 (en) 2010-10-22
EP1799703A2 (de) 2007-06-27
KR101317131B1 (ko) 2013-10-10
HRP20140216T1 (hr) 2014-06-06
ES2451006T3 (es) 2014-03-26
BRPI0515033B1 (pt) 2021-05-25
ATE454396T1 (de) 2010-01-15
HK1156637A1 (en) 2012-06-15
ES2338138T3 (es) 2010-05-04
CA2579656A1 (en) 2006-03-16
NO20071632L (no) 2007-06-05
CY1110280T1 (el) 2015-01-14
EP2361924B1 (de) 2013-12-11
SI2177528T1 (sl) 2012-04-30
US20060052586A1 (en) 2006-03-09
JP5149008B2 (ja) 2013-02-20
PT2361924E (pt) 2014-03-13
BRPI0515033A8 (pt) 2019-01-22
BRPI0515033A (pt) 2008-07-01
PL2361924T3 (pl) 2014-08-29
SI1799703T1 (sl) 2010-04-30
RS51257B (sr) 2010-12-31
EP1799703B1 (de) 2010-01-06
WO2006029393A8 (en) 2007-04-19
EP2361924A1 (de) 2011-08-31
UA91029C2 (uk) 2010-06-25
MX2007002760A (es) 2007-05-18
RS53248B (en) 2014-08-29
RU2007112956A (ru) 2008-10-20
DK1799703T3 (da) 2010-04-19
CN101166754B (zh) 2014-04-23
DK2177528T3 (da) 2012-03-26
ATE536363T1 (de) 2011-12-15
NZ554018A (en) 2009-06-26
WO2006029393A2 (en) 2006-03-16
SI2361924T1 (sl) 2014-04-30
CA2579656C (en) 2014-11-04
IL181596A (en) 2015-10-29
AU2005282249A1 (en) 2006-03-16
KR20070059137A (ko) 2007-06-11
JP2008512494A (ja) 2008-04-24

Similar Documents

Publication Publication Date Title
DE602005018800D1 (de) Verfahren zur herstellung von polypeptidmischungen unter anwendung von aufgereinigter bromwasserstoffsäure
DE60320362D1 (de) Verfahren zur Herstellung von Dipeptiden
UA93669C2 (ru) Способ приготовления полипептидной смеси c использованием гидрогенолиза
ATE462000T1 (de) Verfahren zur herstellung von l-arginin, l- ornithin oder l-citrullin
DE60230274D1 (de) Verfahren zur herstellung von l-aminosäuren durch enterobacteriaceae-stämmen mit verstärkter expression des pts-g
ATE411281T1 (de) Verfahren zur herstellung von s-aryl-cystein
DE602004028239D1 (de) Protease, für die protease codierende dna und verfahren zur herstellung der protease
DE602005016857D1 (de) Verfahren zur Herstellung von Tripeptid-Zwischenprodukten zur Herstellung von LHRH-Antagonisten
ATE479745T1 (de) Nukleotidsequenzen codierend für deregulierte phosphoglycerat-dehydrogenasen coryneformer bakterien sowie verfahren zur herstellung von l- serin
ATE556135T1 (de) Neues protein
CY1115096T1 (el) Διαδικασια για την παρασκευη μιγματων trifluoroacetyl glatiramer acetate χρησιμοποιωντας καθαρισμενο υδροβρωμικο οξυ
DE60321443D1 (de) Screening-verfahren für eine prophylaktische und therapeutische Substanz für eine Nierenerkrankung

Legal Events

Date Code Title Description
8363 Opposition against the patent